Lipoprotein(a) throughout life in women

Area of Science:

• Cardiology
• Genetics
• Endocrinology

Background:

• Lipoprotein (a) [Lp(a)] is a significant cardiovascular risk factor due to its pro-atherogenic, pro-thrombotic, and pro-inflammatory properties.
• Elevated Lp(a) is linked to atherosclerotic vascular disease, aortic valve calcification, and increased all-cause mortality.
• Lp(a) levels are over 90% genetically determined, with minimal influence from lifestyle factors, underscoring the need for lifetime testing.

Purpose of the Study:

• To review and analyze the impact of distinct life stages on Lp(a) levels in women.
• To assess the clinical significance of these Lp(a) level variations concerning cardiovascular risk in females.
• To highlight the role of female sex hormones in modulating cardiovascular risk across a woman's lifespan.

Main Methods:

• Literature review and synthesis of existing studies on Lp(a) and female physiology.
• Analysis of data correlating life stages (e.g., menarche, pregnancy, menopause) with Lp(a) concentrations.
• Evaluation of cardiovascular outcomes associated with Lp(a) variations in women.

Main Results:

• Lp(a) levels exhibit dynamic changes throughout a woman's life, influenced by hormonal fluctuations.
• Cardiovascular risk associated with Lp(a) may be underestimated in women, particularly during specific life phases.
• Evidence suggests women's cardiovascular risk can be equal to or greater than men's, partly due to hormonal influences on Lp(a).

Conclusions:

• Understanding life-stage-specific Lp(a) dynamics is crucial for accurate cardiovascular risk assessment in women.
• Hormonal changes across a woman's lifespan significantly impact Lp(a) levels and associated CV risk.
• Further research is warranted to optimize cardiovascular risk management strategies for women based on Lp(a) levels throughout their lives.